Novartis could lose years of patent protection in the US for its blockbuster multiple sclerosis therapy Gilenya, after a federal appeals verdict went against the company.
Three years after Daiichi Sankyo's FLT3 inhibitor quizartinib was rejected by the FDA, the drugmaker has reported the results of a new phase 3 trial that is key to getting the drug to the U
Amgen is planning to push its olpasiran candidate for reducing lipoprotein(a) into phase 3 as quickly as possible as it tries to catch up with rival programmes at Novartis.
Roche and PTC Therapeutics' Evrysdi for spinal muscular atrophy (SMA) has been approved by the FDA for younger children with the rare disease, extending its use to include infants less than
People who trust pharma are more interested in using the industry’s services – making building confidence in the sector key to realising the potential of patient centricity.